secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001104659-23-114809
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase receives Nasdaq deficiency notice; bid price below $1.00 for 30 days
----------------------------------------------------------------------------

- Nasdaq notified NeuBase on Nov 3, 2023 that its common stock bid price has been below $1.00 for 30 consecutive business days.
- Company has 180 days, until May 1, 2024, to regain compliance by closing at $1.00 or higher for at least 10 consecutive business days.
- If not cured by May 1, NeuBase may qualify for a second 180-day period by meeting other listing standards and providing a reverse split plan.
- The notice does not immediately affect trading on Nasdaq; stock continues to trade under symbol NBSE.
- Company intends to monitor bid price and consider options to regain compliance, but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000110465923114809/0001104659-23-114809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000110465923114809/tm2330001d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer